SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

Brad P. Glick, DO, MPH, FAAD
Director of South Florida Psoriasis Treatment Centers
Clinical Assistant Professor of Dermatology FIU Herbert Wertheim College of Medicine
Miami, FL

Deborah Paschal, CRNP
Clinical Nurse Practitioner
Jefferson Northeast Frankford Hospital, Endocrine Division
Philadelphia, PA

: Atopic Dermatitis: New Insights, New Therapies
Activity/Course #:
: NCME353x

: Free
Release/Start Date:
: Aug 01 2018
Expiration Date:
: Jul 31 2019
: Dermatology
Target Audience:
: Dermatologists and Primary Care Providers
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 0
Hardware/Software Requirements:

Program Summary:

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching, secondary skin infections, recurrent eczematous lesions, and poses a significant burden on healthcare resources and patients' quality of life. The disease is associated with several comorbidities, including mental health disorders (depression, anxiety, autism, ADHD), hypertension, obesity, infections, osteoporosis, fractures, vitiligo, alopecia areata, visual problems, and dental issues.

The disease affects up to 20% of children and up to 3% of adults. Although it is a frequent disease, AD is underdiagnosed and undertreated. It is estimated that 1.6 million adults with moderate-to-severe AD in the United States remain uncontrolled.

Fortunately, new and emerging therapies exist that can dramatically improve AD. This webcast, featuring an interactive discussion between the moderator and faculty responding to live audience questions, will provide an overview of the clinical presentations, comorbidities, diagnosis, and treatments of AD.

This webcast was recorded at the Live Virtual Symposium Emerging Challenges in Primary Care 2018 and is being used with the permission of the presenters.

Learning Objective(s):

After completing this program participants should be able to:

  1. Review and characterize the clinical features of atopic dermatitis (AD)
  2. Discuss the current immuno-pathophysiology of AD
  3. Identify strategies for comprehensive treatment of atopic dermatitis in pediatric and adult populations
  4. Evaluate the clinical application of emerging therapies including topical and targeted biologic agents in the management of AD

How to obtain the CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education (which includes 0.75 pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Dr. Brad P. Glick serves as a speaker for Lilly, Novartis, Abbvie, Sanofi, Regeneron, Leo, Celegne, Vanska, Pfizer and as an Advisor for Top MD.

Contributing Faculty
Dr. Hebert serves as a researcher for Promins, GSK, Mayne, Sienna, Amgen, Medimetriks, Galderma, and Celgene; She serves on the Data and Safety Monitoring Board for GlaxoSmithKline and Sanofi-Regeneron. Dr. Hebert also serves as a speaker for Pfizer, Amgen, and Valeant.

Dr. Yamauchi serves as a speaker, consultant, and investigator for Regeneron, and Pfizer. He also serves as a speaker for Sanofi-Aventis.

Activity Planning Committee
Gregg Sherman, MD, has no relationships to disclose.

Deborah Paschal, CRNP, Moderator, has no relationship to disclose.

Josh Kilbridge, Medical Writer, has no relationship to disclose.

Harvey C. Parker, Ph.D, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Sheila Lucas, CWEP, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationship to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.